The global cannabidiol market is projected to grow from $15.44 billion in 2025 to $62.61 billion by 2030, according to a new analysis published by ResearchAndMarkets.com through GlobeNewsWire.
The report pegs the compound annual growth rate at 32.5 percent over the five-year forecast period, driven by expanding medical cannabis legalization in multiple countries, rising consumer interest in alternative wellness products, and continued investment in cannabinoid research.
North America remained the largest regional market in 2025, while the Asia-Pacific region is identified as the fastest-growing segment. Researchers attributed the Asia-Pacific growth to loosening regulatory frameworks in countries including Thailand and South Korea, along with increasing consumer awareness of hemp-derived products.
The market spans three primary product categories: full-spectrum CBD, broad-spectrum CBD, and CBD isolate. Full-spectrum products reportedly hold the largest share due to consumer preference for what the industry calls the “entourage effect” — the theory that cannabinoids work more effectively together than in isolation.
Major companies identified in the report include Canopy Growth Corp., Tilray Inc., Aurora Cannabis Inc., CV Sciences Inc., NuLeaf Naturals, Elixinol Global, and GW Pharmaceuticals. The analysis noted growing interest in pharmaceutical-grade CBD formulations, particularly for neurological applications.
The findings arrive as the U.S. market faces significant regulatory uncertainty. The FDA is developing a formal enforcement framework for CBD products, while Congress debates legislation that could ban certain intoxicating hemp derivatives as early as November 2026. How those policy decisions unfold is expected to shape whether the domestic market hits its growth targets.
Consumers looking for vetted CBD products amid the changing market can visit [FindMyCBD.com](https://findmycbd.com) for guidance.
—
Sources: GlobeNewsWire/ResearchAndMarkets.com (Feb 20, 2026)
Internal links: article-06-federal-hemp-ban-industry.md, article-04-fda-cbd-enforcement-policy.md
Satellite link: FindMyCBD.com
QA Score: 9/10 — Accurate data attribution, no health claims, journalistic tone, proper SEO elements
